The occurrence of pancreastatin in tumours of the diffuse neuroendocrine system.
We have reported previously the localization of the 49 amino acid peptide pancreastatin to all identifiable endocrine cells of porcine gut, pancreas and adrenal, thyroid and pituitary glands. In this study, we have investigated the occurrence of pancreastatin in a series of human neuroendocrine tumours using an antibody to whole synthetic porcine pancreastatin. The most consistent immunostaining for pancreastatin was found in carcinoid tumours of ileum (four out of six), rectum (four out of six), ovary (two out of two) and lung (nine out of 10). Radioimmunoassay of tumour extracts showed that the concentrations of pancreastatin in ileal carcinoids were very high (mean 71.6, range 31.0-184.0 pmol g-1). The high rate of positivity in lung carcinoids contrasted sharply with the results of 10 pulmonary small cell carcinomas which displayed no immunoreactivity and contained minimal concentrations of pancreastatin (mean 2.0, range 0-6.0 pmol g-1). Extra-adrenal paragangliomas also contained pancreastatin (seven out of 10), but although radioimmunoassay detected peptide in phaeochromocytomas (mean 29.8, range 8.0-69.0 pmol g-1), immunocytochemistry did not. Porcine pancreastatin shows structural homology with bovine chromogranin A, an observation which has led to suggestions that chromogranin is a precursor for the peptide. More recently, a sequence homologous to porcine pancreastatin has been identified in the human chromogranin A molecule. In this study, immunostaining with an antiserum to human chromogranin gave positive results in most cases of each tumour type except the small cell carcinomas. The lack of consistent relationships between chromogranin and pancreastatin immunoreactivities may reflect the fact that the antiserum to pancreastatin was raised against the porcine peptide. When antibodies to human pancreastatin become available, the peptide may prove to be a more consistent marker for neuroendocrine tumours.
Bishop
A E
AE
Department of Histochemistry, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Bretherton-Watt
D
D
Hamid
Q A
QA
Fahey
M
M
Shepherd
N
N
Valentino
K
K
Tatemoto
K
K
Ghatei
M A
MA
Bloom
S R
SR
Polak
J M
JM
D000230:Adenocarcinoma / Q000032:analysis; D000310:Adrenal Gland Neoplasms / Q000032:analysis; D002276:Carcinoid Tumor / Q000032:analysis; D018288:Carcinoma, Small Cell / Q000032:analysis; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis; D003429:Cross Reactions; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000032:analysis; D009369:Neoplasms / Q000032:analysis* / Q000473:pathology; D010187:Pancreatic Hormones / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000032:analysis; D010673:Pheochromocytoma / Q000032:analysis; D011863:Radioimmunoassay
D053379:Chromogranin A; D002864:Chromogranins; D010187:Pancreatic Hormones; C050836:pancreastatin